FY2024 EPS Estimates for Neurogene Lifted by HC Wainwright

Neurogene Inc. (NASDAQ:NGNE) – HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Neurogene in a report issued on Tuesday, November 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($4.34) per share for the year, up from their prior estimate of ($4.42). HC Wainwright currently has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Neurogene’s Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.19) EPS.

Several other equities research analysts have also commented on NGNE. William Blair restated an “outperform” rating on shares of Neurogene in a research report on Tuesday. Leerink Partners upped their target price on Neurogene from $45.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Robert W. Baird upped their target price on Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Stifel Nicolaus increased their price target on Neurogene from $44.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, November 12th. Finally, BMO Capital Markets cut their price target on Neurogene from $60.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $60.83.

Neurogene Stock Performance

Shares of Neurogene stock opened at $15.59 on Thursday. Neurogene has a one year low of $12.49 and a one year high of $74.49. The stock’s 50-day moving average is $45.41 and its 200 day moving average is $39.62.

Institutional Trading of Neurogene

A number of institutional investors and hedge funds have recently modified their holdings of NGNE. Barclays PLC grew its holdings in Neurogene by 319.4% during the third quarter. Barclays PLC now owns 14,859 shares of the company’s stock valued at $623,000 after purchasing an additional 11,316 shares during the period. Jane Street Group LLC bought a new position in Neurogene during the third quarter valued at $324,000. Wellington Management Group LLP bought a new position in Neurogene during the third quarter valued at $767,000. State Street Corp grew its holdings in Neurogene by 17.5% during the third quarter. State Street Corp now owns 246,540 shares of the company’s stock valued at $10,345,000 after purchasing an additional 36,687 shares during the period. Finally, RTW Investments LP grew its holdings in Neurogene by 6.0% during the third quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock valued at $47,635,000 after purchasing an additional 64,691 shares during the period. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.